安德罗格拉福利德通过干扰p300来调节H3基因素乳化,以缓解大动脉的化
Chunli Wang1,2,3, Shunshun Wang3, Zijun Wang3
1School of Laboratory Medicine, Hubei University of Chinese Medicine, Wuhan, China.
British journal of pharmacology
|February 20, 2024
概括
安德罗格拉福利德 (AGP) 通过向p300来抑制组素乳酸化 (H3Kla) 来缓解性大动脉病 (CAVD). 这一发现为预防CAVD进展提供了潜在的新药物策略.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 心血管研究研究心血管研究
背景情况:
- 动脉疾病 (CAVD) 是一个日益严重的临床问题,其潜在机制尚不清楚.
- 安德罗格拉福利德 (AGP) 已显示出缓解CAVD的潜力,但其分子标仍然难以捉摸.
研究的目的:
- 阐明AGP在抑制CAVD中的分子标和信号通路.
- 为了研究基因组乳化 (H3Kla) 在CAVD病变发生过程中的作用以及AGP对它的影响.
主要方法:
- 使用AGP处理进行大动脉结石化的体外和体外模型.
- 阿利扎林红色染色,超声波和组织病理学评估.
- 分子对接,表面等离子体共振 (SPR) 和基因操纵 (过度表达/沉默) 来识别和验证AGP的标 (p300) 以及它对H3Kla.的影响.
主要成果:
- 在小鼠模型中,AGP显著降低了膜间歇细胞中的沉积,并改善了大动脉的化.
- 鉴定出 histone 乳酸化 (H3Kla) 是一种促进大动脉结石化的新型因素.
- 证实p300是AGP的直接分子标,介导抑制H3Kla,随后减少Runx2表达.
结论:
- 通过向p300酶来抑制H3Kla,AGP减轻了CAVD,这是该疾病中关键的翻译后修饰.
- 该机制强调p300和H3Kla作为开发新型抗CAVD药物的潜在治疗点.
相关概念视频
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
513
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
513
Antihypertensive Drugs: Action of Calcium Channel Blockers
518
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
518
Heart Failure Drugs: Inotropic Agents
588
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
588
Antihypertensive Drugs: Angiotensin II Receptor Blockers
731
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
731
Antihypertensive Drugs: Vasodilators
524
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
524
Adrenergic Antagonists: ɑ and β-Receptor Blockers
448
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
448


